Indolent mantle cell lymphoma

Leukemia and Lymphoma

Volumn 55, Issue 4, 2014, Pages 761-767

  Hsi, Eric D ^a   Martin, Peter ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Indolent; Mantle cell lymphoma; Prognosis; SOX11

Indexed keywords

CANCER PROGNOSIS; CLINICAL FEATURE; HUMAN; INDOLENT MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; NON NODAL MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW; CANCER STAGING; DISEASE COURSE; LYMPHOMA, MANTLE-CELL; MORTALITY; PROGNOSIS;

DISEASE PROGRESSION; HUMANS; LYMPHOMA, MANTLE-CELL; NEOPLASM STAGING; PROGNOSIS;

EID: 84904339133     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.815353     Document Type: Review

References (53)

1. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:1209-1213.
2. Eve HE, Furtado MV Hamon MD, et al. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol 2009;27:e189-e190.
3. Fernandez V Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408-1418.
4. Nodit L, Bahler D, Jacobs S, et al. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol 2003;34:1030-1034. (Pubitemid 37315255)
5. Thieblemont C, Houlgatte R, Felman P, et al. Indolent mantle cell lymphoma (MCL):a retrospective detailed clinical and morphological analysis of 21 patients, with histological, cytological, cytogenetic, interphase genetic, immunoglobulin gene, and gene expression profiling analysis. Blood 2008;112(Suppl. 1): Abstract 1780.
6. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984-1992. (Pubitemid 46211378)
7. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of the haematopoietic and lymphoid tissues. Lyon: IARC; 2008.pp 270-319.
8. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood 2007;111:558-565.
9. Geisler CH, Kolstad A, Laurell A, et al.;Nordic Lymphoma Group. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010;115: 1530-1533.
10. Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP- rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 690-697.
11. Budde LE, Guthrie KA, Till BG, et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-Cell transplantation. J Clin Oncol 2011;29:3023-3029.
12. van de Schans SAM, Janssen-Heijnen MLG, Nijziel MR, et al. Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting. Haematologica 2010; 95: 1503-1509.
13. Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012; 122: 3416-3423.
14. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185-197. (Pubitemid 37443390)
15. Determann O, Hoster E, Ott G, et al.;European Mantle Cell Lymphoma Network and German Low Grade Lymphoma Study Group. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:2385-2387. (Pubitemid 351451450)
16. Hoster E, Dreyling M, Klapper W, et al.;German Low Grade Lymphoma Study Group and European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced- stage mantle cell lymphoma. Blood 2008; 111: 558-565.
17. Klapper W, Hoster E, Determann O, et al. Ki-67 as a prognostic marker in mantle cell lymphoma consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2009;2:103-111.
18. Schaffel R, Hedvat CV, Teruya-Feldstein J, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 2010; 21: 133-139.
19. Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012; 119: 4597-4607.
20. Brepoels L, Stroobants S, De Wever W, et al. Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma 2008;49: 1693-1701.
21. Angelopoulou MK, Siakantariz MP, Vassilakopoulos TP, et al. The splenic form of mantle cell lymphoma. Eur J Haematol 2002;68: 12-21. (Pubitemid 34407538)
22. Cohen PL, Kurtin PJ, Donovan KA, et al. Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol 1998; 101: 302-310. (Pubitemid 28261118)
23. Ondrejka SL, Lai R, Smith SD, et al. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011; 96: 1121-1127.
24. Orchard J, GarandR, DavisZ, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003;101: 4975-4981. (Pubitemid 36857762)
25. RuchlemerR, Wotherspoon AC, Thompson JN, et al. Splenectomy in mantle cell lymphoma with leukaemia: a comparison with chronic lymphocytic leukaemia. Br J Haematol 2002; 118: 952-958. (Pubitemid 35025956)
26. Yoong Y, Kurtin PJ, Allmer C, et al. Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma. Leuk Lymphoma 2001; 42: 1235-1241. (Pubitemid 34082910)
27. Matutes E, Parry-Jones N, Brito-Babapulle V, et al. The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients. Leuk Lymphoma 2004;45:2007-2015. (Pubitemid 39232849)
28. Orchard J, Garand R, DavisZ, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003;101: 4975-4981. (Pubitemid 36857762)
29. MatutesE, Owusu-AnkomahK, MorillaR, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640-1645. (Pubitemid 24323778)
30. Penzo-Mendez AI.Critical roles for SoxC transcription factors in development and cancer. Int J Biochem Cell Biol 2010;42: 425-428.
31. Lefebvre V Dumitriu B, Penzo-Mendez A, et al. Control of cell fate and differentiation by Sry-related high-mobility-group Box (Sox) transcription factors. Int J Biochem Cell Biol 2007;39:2195-2214. (Pubitemid 47484275)
32. Dictor M, Ek S, Sundberg M, et al. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica 2009; 94: 1563-1568.
33. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009; 94: 1555-1562.
34. Zeng W, Fu K, Quintanilla-Fend L, et al. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. Am J Surg Pathol 2012; 36: 214-219.
35. Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012; 72: 5307-5316.
36. Nygren L, Baumgartner Wennerholm S, Klimkowska M, et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 2012; 119: 4215-4223.
37. Royo C, Navarro A, Clot G, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 2012; 26: 1895-1898.
38. Rawstron AC, Bennett FL, O'Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008; 359: 575-583.
39. Jegalian AG, Eberle FC, Pack SD, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement byfollicular lymphoma. Blood 2011; 118: 2976-2984.
40. Landgren O, Kyle RA, Rajkumar SV. From myeloma precursor disease to multiple myeloma:new diagnostic concepts and opportunities for early intervention. Clin Cancer Res 2011;17: 1243-1252.
41. Espinet B, Sole F, Pedro C, et al. Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient:an early- stage event in the development or an indolent form of a mantle cell lymphoma? Hum Pathol 2005;36:1232-1237. (Pubitemid 41540401)
42. Nodit L, Bahler DW, Jacobs SA, et al. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol 2003;34:1030-1034. (Pubitemid 37315255)
43. Racke F, Simpson S, Christian B, et al. Evidence of long latency periods prior to development of mante cell lymphoma. Blood 2010;116(Suppl. 1): Abstract 2834.
44. Adam P, Schiefer AI, Prill S, et al. Incidence of preclinical manifestations of mantle cell lymphoma and mantle cell lymphoma in situ in reactive lymphoid tissues. Mod Pathol 2012; 25: 1829-1836.
45. Carvajal-Cuenca A, Sua LF, Silva NM, et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 2012; 97: 270-278.
46. Royo C, Salaverria I, Hartmann EM, et al. The complexlandscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol 2011; 21: 322-334.
47. Lecluse Y, LebaillyP, Roulland S, et al. t(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals. Leukemia 2009; 23: 1190-1193.
48. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:2385-2387. (Pubitemid 351451450)
49. Hsi ED, Jung SH, Lai R, et al. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab:a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma 2008;49:2081-2090.
50. Katzenberger T, Petzoldt C, Holler S, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006;107(Suppl. 1): Abstract 3407.
51. Salaverria I, Zettl A, Bea S, et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007;25:1216-1222. (Pubitemid 46640567)
52. Halldorsdottir AM, Lundin A, Murray F, et al. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. Leukemia 2011; 25: 1904-1908
53. Slotta-Huspenina J, Koch I, de Leval L, et al. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index. Haematologica 2012; 97: 1422-1430.